Page 3 - Nasdaq Ortx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cantor Fitzgerald restated their overweight rating on shares of Orchard Therapeutics (NASDAQ:ORTX – Get Rating) in a report released on Monday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Orchard Therapeutics’ FY2023 earnings at ($6.25) EPS. Separately, Oppenheimer increased their price target on Orchard Therapeutics from $5.00 to $37.00 in a research note on Monday, […]

Orchard Therapeutics (NASDAQ:ORTX – Get Rating) released its quarterly earnings data on Monday. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($1.61) by $1.49, MarketWatch Earnings reports. Orchard Therapeutics had a negative net margin of 665.02% and a negative return on equity of 110.80%. The business had revenue of $1.24 […]

Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 129,300 shares, a growth of 46.9% from the March 15th total of 88,000 shares. Currently, 0.8% of the shares of the stock are sold […]

Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 129,300 shares, a growth of 46.9% from the March 15th total of 88,000 shares. Approximately 0.8% of the company’s shares are sold short. Based on an average […]

Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) – Analysts at Cantor Fitzgerald lifted their FY2023 EPS estimates for Orchard Therapeutics in a research report issued on Tuesday, March 28th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings of ($6.25) per share for the year, up from their prior estimate of […]